More Positive Phase 3 Results ' Raise the Bar ' for Migraine Drug More Positive Phase 3 Results ' Raise the Bar ' for Migraine Drug

Secondary analyses of the phase 3 ADVANCE trial showed atogepant, a CGRP receptor antagonist, is superior to placebo across several migraine responder outcomes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news